Tag Archives: Visiopharm

October 2023—Visiopharm and Boston Cell Standards announced they are partnering to integrate immunohistochemistry calibration standards with image analysis software for quality assurance. The joint technology solution will enable laboratories to meet key provisions of regulatory changes proposed in an editorial published in Archives of Pathology & Laboratory Medicine.

Sept. 19, 2023—Evident announced an alliance with Corista, Sakura Finetek, and Visiopharm to deliver an automated, end-to-end workflow solution for pathology in the United States.

June 2023—Visiopharm announced the launch of a next-generation Ki-67 algorithm designed to automate the scoring of Ki-67 slides. Tumor nuclei are counted based on their Ki-67 expression and the resulting proliferation index for the whole tumor area is calculated. The algorithm has been cleared under the European Union in vitro diagnostic regulation and is for research use only in the United States.  

February 2017—Visiopharm A/S, headquartered in Hørsholm, Denmark, announced its acquisition of LRI Imaging AB, based in Sweden.